Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer

Home Shopping Network Settles FTC Unsubstantiated Ad Claims Case

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

The Home Shopping Network will pay a $1.1 mil. civil penalty to settle Federal Trade Commission charges that the network aired advertisements with unsubstantiated claims for weight loss, PMS/ menopause and skin care products, the FTC announced April 15. The commission has ordered HSN and its subsidiary, Home Shopping Club, not to make any further ad claims it cannot substantiate.

You may also be interested in...



Weider FTC Weight Loss Charges Settled For $400,000

Weider Nutrition Internatl. has agreed to pay $400,000 to settle Federal Trade Commission charges the firm misrepresented the science supporting weight loss and safety claims for its Schiff PhenCal products.

Weider FTC Weight Loss Charges Settled For $400,000

Weider Nutrition Internatl. has agreed to pay $400,000 to settle Federal Trade Commission charges the firm misrepresented the science supporting weight loss and safety claims for its Schiff PhenCal products.

Weider FTC Weight Loss Charges Settled For $400,000

Weider Nutrition Internatl. has agreed to pay $400,000 to settle Federal Trade Commission charges the firm misrepresented the science supporting weight loss and safety claims for its Schiff PhenCal products.

Table

View full table

Topics

Tags:
Consumer
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS089681

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By